Abstract
Therapeutic targets for halting the progression of Alzheimers disease pathology are lacking. Recent evidence suggests that APOE4, but not APOE3, activates the cyclophilin A matrix metalloproteinase-9 (CypA MMP9) pathway in the cerebrospinal fluid, arguing that this led to an accelerated breakdown of the blood brain barrier (BBB) and thereby causing neuronal and synaptic dysfunction. Furthermore, blockade of the CypA MMP9 pathway in APOE4 knock-in mice restores BBB integrity and subsequently normalizes neuronal and synaptic function. Thus, CypA has been suggested as a potential target for treating APOE4 mediated neurovascular injury and the resulting neuronal dysfunction and degeneration. The odds of drug targets passing through clinical trials are greatly increased if they are supported by genomic evidence. We found little evidence that CypA or MMP9 affected the risk of Alzheimers disease or cognitive impairment using two-sample Mendelian randomization and polygenic risk score analysis in humans. This casts doubt on whether they are likely to represent effective drug targets for cognitive impairment in APOE4 carriers.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
ELA is supported by a fellowship from the UK Medical Research Council (MR/P014437/1). The Medical Research Council (MRC) and the University of Bristol support the MRC Integrative Epidemiology Unit [MC_UU_00011/1]. NMD is supported by a Norwegian Research Council Grant number 295989. DMW. is funded by the United Kingdom's Medical Research Council (MC_UU_00019/2). The Medical Research Council (MRC) and the University of Bristol support the MRC Integrative Epidemiology Unit (MC_UU_12013/1, MC_UU_12013/9, MC_UU_00011/1).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The UK Biobank Ethics Advisory Committee (EAC) is a Committee of the UK Biobank Board whos remit is to provide advice to the Board on ethical issues that arise during the maintenance, development and use of UK Biobank. The UK Biobank was approved by the North West Research Ethics committee. Approval was received to use UK Biobank data in the present work and the access to the data was granted after registration (ID: 19278). No ethical approval was required for the two-sample MR analyses which uses summary statistics and contains no individual-level data.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
eQTL and pQTL genome-wide association study summary statistics are available on the MR-Base platform. Alzheimer's disease summary statistics are available from the following website: https://ctg.cncr.nl/software/summary_statistics
